drugset / Trial / NCT02915523
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Phase 1/2
Completed
140 enrolled
Syndax Pharmaceuticals
Merck KGaA, Darmstadt, Germany · collabPfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this study will evaluate the effectiveness of entinostat in combination with avelumab at the determined dose in terms of progression free survival compared to avelumab plus placebo in participants with refractory or recurrent epithelial ovarian cancer.
Timeline
- Start
- 2016-12-19
- Primary completion
- 2019-02-21
- Completion
- 2021-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Avelumab | Monoclonal antibody | — | Intravenous |
| Comparator | Entinostat | Small molecule | — | Oral |